Analysis of Coronary Stent in US
The US represents the world’s largest healthcare market, with a high annual healthcare spending. The US market for healthcare holds a great potential and presents immense opportunities for the industry players aiming to expand operations while addressing the reduction of healthcare expenditures, which is the biggest issue. The growth in healthcare spending is mainly driven by high administrative costs, growing technology and prescription drugs, and a severe rise in chronic diseases. According to our report “Analysis of Coronary Stent in US”, reducing the burden of chronic diseases will have a significant impact on reducing national healthcare expenditure in US.
Our report has been developed to portray the burden that cardiovascular diseases (CVD), amongst the various chronic diseases, has on the overall national healthcare expenditure in US, and presents the latest technologies approved by the USFDA to treat related disorders.
The report provides detailed statistical and analytical review of national healthcare expenditure in US, the burden of chronic diseases on healthcare expenditure, and the direct and indirect costs associated with CVD and its various types such as hypertension, chronic heart disease, heart failure and stroke. The report also provides the existing and future market dynamics of the coronary stent market in US.
Further, the report provides a detailed analysis of the 2012 FDA Approved Stents covering the stent manufacturing company, stent description and targeted disease conditions, and most importantly, the key market capturing features that will drive their growth in the industry.
The report also provides company profiling of the leading players in the stent business along with their hold in stent market based on recent activity and product portfolio. Overall, the report provides an easy to comprehend comparison of the latest stent products, latest developments, and direction for growth in the US stent market.
Our report has been developed to portray the burden that cardiovascular diseases (CVD), amongst the various chronic diseases, has on the overall national healthcare expenditure in US, and presents the latest technologies approved by the USFDA to treat related disorders.
The report provides detailed statistical and analytical review of national healthcare expenditure in US, the burden of chronic diseases on healthcare expenditure, and the direct and indirect costs associated with CVD and its various types such as hypertension, chronic heart disease, heart failure and stroke. The report also provides the existing and future market dynamics of the coronary stent market in US.
Further, the report provides a detailed analysis of the 2012 FDA Approved Stents covering the stent manufacturing company, stent description and targeted disease conditions, and most importantly, the key market capturing features that will drive their growth in the industry.
The report also provides company profiling of the leading players in the stent business along with their hold in stent market based on recent activity and product portfolio. Overall, the report provides an easy to comprehend comparison of the latest stent products, latest developments, and direction for growth in the US stent market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. HEALTHCARE EXPENDITURE - CARDIOVASCULAR DISEASES
3.1 High Healthcare Expenditure in US - The Issue
3.2 Reasons for High Expenditure related to Health
3.3 Burden of Chronic Diseases on Healthcare Expenditure
4. US CORONARY STENT MARKET ANALYSIS TO 2017
5. TECHNOLOGY ASSESSMENT: 2012 FDA APPROVED STENTS
5.1 Zilver PTX Stent
5.2 S.M.A.R.T. CONTROL Stent System
5.3 Medtronic Valiant Thoracic Stent Graft
5.4 OVATION Abdominal Stent Graft
5.5 Omnilink Elite Stent System
5.6 Relay Thoracic Stent-Graft
5.7 PROMUS Element Stent System
5.8 Presillion plus Stent
5.9 Epic Vascular Stent System
5.10 Zenith Fenestrated AAA Endovascular Graft
5.11 EverFlex Self-Expanding Peripheral Stent System
5.12 TAXUS Liberté Stent System
5.13 TAXUS Express2 Stent System
5.14 ION Coronary Stent System
5.15 Resolute MicroTrac and Resolute Integrity Coronary Stent System
5.16 Absolute Pro Vascular Stent System
5.17 GORE TAG Stent Graft
6. COMPETITIVE ANALYSIS
6.1 Covidien
6.1.1 Business Description
6.1.2 Company Presence in Stent Business
6.2 Medtronic
6.2.1 Business Description
6.2.2 Company Presence in Stent Business
6.3 Boston Scientific
6.3.1 Business Description
6.3.2 Company Presence in Stent Business
6.4 W.L. Gore & Associates
6.4.1 Business Description
6.4.2 Company Presence in Stent Business
6.5 Cordis Corporation
6.5.1 Business Description
6.5.2 Company Presence in Stent Business
2. RESEARCH METHODOLOGY
3. HEALTHCARE EXPENDITURE - CARDIOVASCULAR DISEASES
3.1 High Healthcare Expenditure in US - The Issue
3.2 Reasons for High Expenditure related to Health
3.3 Burden of Chronic Diseases on Healthcare Expenditure
4. US CORONARY STENT MARKET ANALYSIS TO 2017
5. TECHNOLOGY ASSESSMENT: 2012 FDA APPROVED STENTS
5.1 Zilver PTX Stent
5.2 S.M.A.R.T. CONTROL Stent System
5.3 Medtronic Valiant Thoracic Stent Graft
5.4 OVATION Abdominal Stent Graft
5.5 Omnilink Elite Stent System
5.6 Relay Thoracic Stent-Graft
5.7 PROMUS Element Stent System
5.8 Presillion plus Stent
5.9 Epic Vascular Stent System
5.10 Zenith Fenestrated AAA Endovascular Graft
5.11 EverFlex Self-Expanding Peripheral Stent System
5.12 TAXUS Liberté Stent System
5.13 TAXUS Express2 Stent System
5.14 ION Coronary Stent System
5.15 Resolute MicroTrac and Resolute Integrity Coronary Stent System
5.16 Absolute Pro Vascular Stent System
5.17 GORE TAG Stent Graft
6. COMPETITIVE ANALYSIS
6.1 Covidien
6.1.1 Business Description
6.1.2 Company Presence in Stent Business
6.2 Medtronic
6.2.1 Business Description
6.2.2 Company Presence in Stent Business
6.3 Boston Scientific
6.3.1 Business Description
6.3.2 Company Presence in Stent Business
6.4 W.L. Gore & Associates
6.4.1 Business Description
6.4.2 Company Presence in Stent Business
6.5 Cordis Corporation
6.5.1 Business Description
6.5.2 Company Presence in Stent Business
LIST OF FIGURES
Figure 3-1: Break-up of National Healthcare Expenditure (%), 2010
Figure 3-2: Top Drivers for High Healthcare Expenditure
Figure 3-3: Population Affected with Chronic Diseases (%), 2012
Figure 3-4: Population Affected with Multiple Chronic Diseases (%), 2012
Figure 3-5: Prevalence of CVD by Type (%), 2010 to 2030
Figure 3-6: Healthcare Expenditure on CVD (Billion US$), 2010 to 2030
Figure 3-7: Direct Healthcare Expenditure on CVD by Type (Billion US$), 2010 to 2030
Figure 3-8: Indirect Healthcare Expenditure on CVD by Type (Billion US$), 2010 to 2030
Figure 4-1: Share of US in the Global Coronary Stent Market, (2012)
Figure 4-2: Coronary Stent Market (Billion US$), 2012-2017
Figure 4-3: Coronary Stent Market by Stent Type (%), 2017
Figure 3-1: Break-up of National Healthcare Expenditure (%), 2010
Figure 3-2: Top Drivers for High Healthcare Expenditure
Figure 3-3: Population Affected with Chronic Diseases (%), 2012
Figure 3-4: Population Affected with Multiple Chronic Diseases (%), 2012
Figure 3-5: Prevalence of CVD by Type (%), 2010 to 2030
Figure 3-6: Healthcare Expenditure on CVD (Billion US$), 2010 to 2030
Figure 3-7: Direct Healthcare Expenditure on CVD by Type (Billion US$), 2010 to 2030
Figure 3-8: Indirect Healthcare Expenditure on CVD by Type (Billion US$), 2010 to 2030
Figure 4-1: Share of US in the Global Coronary Stent Market, (2012)
Figure 4-2: Coronary Stent Market (Billion US$), 2012-2017
Figure 4-3: Coronary Stent Market by Stent Type (%), 2017
